Optimizing Metabolic Control in Type 1 Diabetes - The Automatic Bolus Calculator Flash Study

Summary

This study aims to compare the effect of flash glucose monitoring (FGM) with traditional self-monitoring of blood glucose (SMBG) with or without carbohydrate counting and automated bolus calculation, in patients with type 1 diabetes and poor metabolic control.

The investigators will include in total 200 patients recruited from 5 clinical sites in the Capital Region of Copenhagen.

The patients will be randomized into four groups; A) Standard diabetes training, i.e. group training in in general diabetes health issues, B) Group training in carbohydrate counting and automated bolus calculation, the app MySugr will be taught and downloaded, C) Group training as in group A, and instructed to use FGM, D) Group training as in group B, and besides training in the use of the app MySugr, also instructed to use FGM.

All patients are followed for 26 weeks with 6 clinical visits, group training (1 visit) and 2 telephone consultations.

The primary outcome is time spent in normoglycemia.

Conditions

• Diabetes Mellitus, Type 1

Interventions

DEVICE

Carbohydrate counting, automated bolus calculation

Group training in carbohydrate counting and bolus calculation. The app MySugr will be taught and downloaded on own smart phone and person specific parameters will be estimated and entered in the app with the patients. SMBG measures at least 4 times daily with patients own preferred glucose meter.

DEVICE

Flash glucose monitoring (FGM)

Group training, patients will be instructed to use unblinded FGM for the whole study period. Patients are recommended to measure SMBG according to FGM manufactures guideline and handling of trend arrows etc.

Sponsors & Collaborators

• Hillerod Hospital, Denmark

  collaborator OTHER

• Hvidovre University Hospital

  collaborator OTHER

• Bispebjerg Hospital

  collaborator OTHER

• Rigshospitalet, Denmark

  collaborator OTHER

• Frederiksberg University Hospital

  collaborator OTHER

• Amager Hospital

  collaborator OTHER

• Steno Diabetes Center Copenhagen

  lead OTHER

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2018-10-01

Primary Completion

2020-10-26

Completion

2020-10-26

Countries

• Denmark

Study Locations